SAN FRANCISCO — As discussed in Tuesday's issue of Medical Device Daily, there has been considerable progress in treating atrial fibrillation (AF) with catheter-based technologies in recent years. However, the rate of success, estimated at 57% for a single procedure, is far from satisfactory. Thus, the quest for better methods to perform AF catheter ablation continues at a strong pace. One company, which is demonstrating impressive progress, is privately-owned, venture capital-backed CardioFocus (Marlborough, Massachusetts). (Medical Device Daily) Read More
